AXON Presented Its Tau Vaccine in Two Presentations at 14Th AAT Conference

ATHENS, Greece–(BUSINESS WIRE)–AXON Neuroscience presented two topics from its disease modifying AD program at the 14th International Athens/Springfield Symposium on Advances in Alzheimer Therapy. In the first presentation Axon introduced the endpoints and the design of the phase II clinical trial with the first active tau vaccine, AADvac1, in patients with mild Alzheimer’s disease. In the second presentation, AXON presented the immunology profile of AADvac1 from the successful Phase I study which was performed in Austria with 30 patients at 4 clinical sites AADVAC1 PHASE II CLINICAL STUDY AXON’s active vaccine AADvac1 is intended to be a disease-modifying drug for Alzheimer’s disease. AXON has previously demonstrated positive results of preclinical research with a significant reduction of tau pathology in transgenic animal models and improvement of their survival and neurobehavioral symptoms.…


Link to Full Article: AXON Presented Its Tau Vaccine in Two Presentations at 14Th AAT Conference